Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TSH BiopharmROCO:8432 84 ROA % is 4.81% as of Dec. 2025, which is 1% below its 10-year median of 4.85. GuruFocus rates ROCO:8432 with a GF Score™ of 84/100 and a GF Value™ of NT$78.92 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 1,009 Drug Manufacturers companies, TSH Biopharm ranks better than 73.14% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. TSH Biopharm's annualizedNet Income for the quarter that ended in Dec. 2025 was NT$95 Mil.
TSH Biopharm's average Total Assets over the quarter that ended in Dec. 2025 was NT$1,985 Mil. Therefore, TSH Biopharm's annualized ROA % for the quarter that ended in Dec. 2025 was 4.81%.
The historical rank and industry rank for TSH Biopharm's ROA % or its related term are showing as below:
ROCO:8432'
s ROA % Range Over the Past 10 Years
Min: 3.93 Med: 4.85 Max: 9.33
Current: 7.3
During the past 13 years, TSH Biopharm's highest ROA % was 9.33%. The lowest was 3.93%. And the median was 4.85%.
ROCO:8432's ROA % is ranked better than 73.14% of 1009
companies
in the Drug Manufacturers industry
Industry Median: 2.74
vs ROCO:8432: 7.30
TSH Biopharm (ROCO:8432) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Dec. 2025) net income data. The Revenue data used here is four times the quarterly (Dec. 2025) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
TSH Biopharm ROA % Related Terms
TSH Biopharm ROA % Historical Data
* Premium members only.
The historical data trend for TSH Biopharm's ROA % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, TSH Biopharm's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TSH Biopharm ROA % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, TSH Biopharm's ROA % distribution charts can be found below:
* The bar in red indicates where TSH Biopharm's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Dec. 2025) net income data.
ROA % is displayed in the 30-year financial page.
TSH Biopharm (ROCO:8432) has a ROA % of 4.81% as of Dec. 2025. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on TSH Biopharm and its competitors. This is near median its historical median of 4.85. Over the past decade, TSH Biopharm's ROA % has ranged from 3.93 to 9.33. According to the industry distribution chart, TSH Biopharm ranks #271 out of 1009 companies in the Drug Manufacturers industry, placing it in the top 26.9%.
Is TSH Biopharm's ROA % too high?
TSH Biopharm's current ROA % of 4.81% is near median its 10-year median of 4.85. Over the past 10 years, this metric has ranged from a low of 3.93 to a high of 9.33. The Drug Manufacturers industry median ROA % is 2.74. TSH Biopharm's value of 4.81% is 75.5% above this industry median. Based on the distribution chart, TSH Biopharm ranks #271 out of 1009 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, TSH Biopharm has a GF Score™ of 84/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does TSH Biopharm's ROA % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, TSH Biopharm ranks #271 out of 1009 companies for ROA %. This puts TSH Biopharm in the upper half of its industry. The industry median ROA % is 2.74. TSH Biopharm's value of 4.81% is 75.5% above this benchmark. Historically, TSH Biopharm's own ROA % has ranged from 3.93 to 9.33 over the past decade. While the company's 10-year median is 4.85 vs. the industry median of 2.74, TSH Biopharm has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Drug Manufacturers company?
The median ROA % among Drug Manufacturers companies is 2.74, based on 1,009 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TSH Biopharm's current ROA % of 4.81% is 75.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on TSH Biopharm and its competitors. For the Drug Manufacturers industry, the median ROA % is 2.74 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TSH Biopharm's current ROA % is 4.81%, which is near median its own 10-year median of 4.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TSH Biopharm stock overvalued right now?
Based on GuruFocus' analysis, TSH Biopharm (ROCO:8432) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$78.92, compared to a current price of NT$50.20 — trading 36.4% below its estimated fair value. The current ROA % is 4.81%, which is near median its 10-year median of 4.85 and 75.5% above the Drug Manufacturers industry median of 2.74. TSH Biopharm's overall GF Score™ is 84/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For TSH Biopharm (ROCO:8432), the current ROA % is 4.81% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TSH Biopharm (ROCO:8432) Overvalued in 2026?
Based on GuruFocus' analysis, TSH Biopharm stock appears to be undervalued.
The current stock price of NT$50.20 is trading 36.4% below its estimated GF Value™ of NT$78.92.
GuruFocus considers TSH Biopharm to be Significantly Undervalued.
Key valuation signals for ROCO:8432:
ROA %: 4.81% (near median its 10-year median of 4.85)
GF Value™: NT$78.92 vs. price of NT$50.20 (36.4% below fair value)
Industry Position: 75.5% above the Drug Manufacturers median (#271 of 1009)
No single metric tells the full story. See the ROCO:8432 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TSH Biopharm Corp Ltd is engaged in sale of a variety of pharmaceuticals, chemical drugs and engaged in biotechnology services. The company specializes in the development, manufacture, and marketing of branded drugs for chronic diseases. Key therapeutic areas include cardiovascular, central nervous system, gastroenterology, and severe chronic diseases, alongside precision medicine/genetic testing services .The Company's revenue is earned domestically. It earns majority of its revenue from the sale of Lozenges.
84GF Score
Get the complete analysis for ROCO:8432
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:8432 has been successfully added to your 
